How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

297 results for

adhd Bupropion

Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

221. Assessing Top Down and Bottom Up Attention Mechanisms in Smokers Using Nicotine Nasal Spray

twice per week during the past month --Drug Use Survey (items 2-4) pregnant or nursing --Urine pregnancy test HIV positive --Oral HIV test untreated cardiovascular or pulmonary disease use of nicotine replacement products, bupropion or varenicline, in the past 3 months if specifically used to stop smoking Past history of schizophrenia or bipolar disorder. Current Major Depression Disorder, Diagnosis or treatment for Major Depressive Disorder in past 12 months. (H&P) Evidence of current ADHD (...) provide more useful information for this research. The ability to pay attention and filter relevant from irrelevant stimuli is central to all aspects of information-processing. Top-down and bottom-up attentional processes illustrate how the brain combines stimuli and goal-directed behaviors. Bottom-up processing is an unconscious response to sensory input; for instance, when the eyes automatically focus on a prominent image in a picture. Top-down processing is a conscious response to drive attention

2010 Clinical Trials

222. Pilot Study of Tolcapone in Smokers

/treatment Phase Nicotine Dependence Drug: Tolcapone Drug: Placebo Phase 2 Detailed Description: Despite decades of research to develop pharmacotherapies for nicotine dependence (ND), with current FDA approved medications (bupropion, varenicline and NRTs) the majority (>60%) of smokers relapse in the first year following treatment (Lerman, Patterson et al. 2005; Tonstad, Tonnesen et al. 2006). Testing novel medications that may reduce abstinence symptoms that prompt smoking relapse is a plausible route (...) Go to Primary Outcome Measures : Number of Eligible Participants Enrolled Who Completed the Study. [ Time Frame: 30 days ] Number of enrolled participants who complete the final study visit Secondary Outcome Measures : N-back (Working Memory) Correct Reaction Time After Overnight Abstinence. [ Time Frame: 30 days ] To obtain preliminary data on the effects of Tolcapone on abstinence-induced neurocognitive deficits in abstinent smokers with differing COMT genotypes. We examined reaction time

2010 Clinical Trials

223. Ecopipam Treatment of Tourette Syndrome

(range 0-25) and vocal (range 0-25) tics , as well as an impairment score (range 0-50). The outcome we are using is the Total Tic Severity score which is the sum of the motor and vocal tic severity scores (range 0-50). The higher the score on this scale, the more severe the symptoms. A positive drug effect is associated with a decrease from baseline. Secondary Outcome Measures : Adult Attention Deficit/Hyperactivity Disorder (ADHD) Self-report Symptom Checklist (ASRS) [ Time Frame: Every 7 days (...) ] This is a standard measure of ADHD severity that is typically used in these types of clinical trials. Hamilton Depression Scale [ Time Frame: Every 7 days ] This is a measure of feelings of depression that the patient might have. Premonitory Urge for Tics Scale (PUTS-1) [ Time Frame: Every 7 days ] This is a measure of the tic behavior that is seen in Tourette's patients, and it is typically used in these types of trials. Clinician Global Impression - Improvement and Severity Scales (CGI) [ Time Frame: End

2010 Clinical Trials

224. Study of Varenicline (Champix) for Smoking Cessation/Reduction in Patients With Bipolar Disorder

weeks; Hypotheses: Varenicline will be superior to placebo for smoking cessation outcomes. Varenicline will be well-tolerated and safe for use in Bipolar I smokers in comparison to placebo. Varenicline will reduce smoking indices (Carbon monoxide, cotinine) and have minimal effects on psychiatric symptomatology in mood-stabilizer treated Bipolar I smoking patients. The presence of prefrontal cortical, impulsivity and attentional deficits on the baseline neuropsychological battery will predict (...) Study of Varenicline (Champix) for Smoking Cessation/Reduction in Patients With Bipolar Disorder Study of Varenicline (Champix) for Smoking Cessation/Reduction in Patients With Bipolar Disorder - Full Text View - Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one

2010 Clinical Trials

225. Pilot Trial of Bupropion Versus Placebo for Methamphetamine Abuse in Adolescents

neurological disorder (e.g., organic brain disease, dementia) or major psychiatric disorder not due to substance abuse (e.g., schizophrenia, bipolar disorder) as assessed by the K-SADS-PL other than attention deficit-hyperactivity disorder (see below) or a medical history which would make study agent compliance difficult or which would compromise informed consent, or history of suicide attempts in the past year and/or current serious suicidal intention or plan as assessed by the K-SADS-PL; currently taking (...) bupropion for depression, smoking cessation or OCD within 30 days of baseline; taking any prescription medication for ADHD; currently on prescription medication that is contraindicated for use with bupropion; have current dependence on cocaine, opiates, alcohol, or benzodiazepines as defined by DSM-IV-TR; have a self-reported history of a seizure disorder or serious closed head injury; have a medical condition (such as serious head injury) that is associated with increased risk of seizures

2009 Clinical Trials

226. Varenicline Treatment for Smoking Cessation in Patients With Bipolar Disorder

for smoking abstinence Secondary Outcome Measures : Participants Experiencing Neuropsychiatric Events [ Time Frame: 24 weeks ] Evaluate the safety of varenicline in treatment-emergent hypomania, mania, mixed or depressed episodes or being associated suicidal or aggressive behavior or psychotic symptoms when used as adjunctive treatment in participants with bipolar disorder. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important (...) after the last dose of study medication or a barrier method of contraception, e.g., condom and/or diaphragm with spermicide while participating in the study through at least 30 days after the last dose of study medication or abstinence. MADRS total scores ≤ 8 (past 4 weeks) (suicidal item, score ≤ 1, past 4 weeks). Y-MRS scores ≤ 8 (past 4 weeks) irritability, speech content, disruptive, or aggressive behavior items score ≤ 3, past 4 weeks) Stable doses of primary bipolar maintenance medication

2009 Clinical Trials

227. Comparing the Effectiveness of New Versus Older Treatments for Attention Deficit Hyperactivity Disorder (The NOTA Study)

terms Attention Deficit Disorder with Hyperactivity Hyperkinesis Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders Dyskinesias Neurologic Manifestations Nervous System Diseases Signs and Symptoms Methylphenidate Amphetamine Lisdexamfetamine Dimesylate Adderall Central Nervous System Stimulants Physiological Effects of Drugs Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms (...) . Condition or disease Intervention/treatment Phase Attention Deficit Disorder With Hyperactivity Drug: Methylphenidate transdermal system Drug: Lisdexamfetamine dimesylate Drug: Osmotic-release oral system methylphenidate (OROS MPH) Drug: Mixed amphetamine salts extended release Phase 4 Detailed Description: Attention deficit hyperactivity disorder (ADHD) is characterized by impulsiveness, hyperactivity, and inattention. It is seen primarily in children and adolescents and is often treated

2009 Clinical Trials

228. Bupropion for ADHD in Adolescents With Substance Use Disorder

Update Posted: May 30, 2013 Last Verified: May 2013 Keywords provided by University of Colorado, Denver: Adolescents Substance Use Disorder Attention Deficit Hyperactivity Disorder Cognitive Behavioral Therapy Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Tobacco Use Disorder Substance-Related Disorders Pathologic Processes Attention Deficit and Disruptive Behavior Disorders Neurodevelopmental Disorders Mental Disorders (...) Party): University of Colorado, Denver Study Details Study Description Go to Brief Summary: Attention deficit hyperactivity disorder (ADHD) is one of the most common co-occurring psychiatric disorders (30-50%) in adolescents with substance use disorders (SUD). Yet, little is known about the safety and efficacy of medications for ADHD in adolescents with SUD, since such youths have been excluded from most medication trials. Clinicians are therefore understandably reluctant to treat ADHD in substance

2009 Clinical Trials

229. Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype

or squamous cell skin cancer); Other major medical condition; Current psychiatric disease (with the exception of anxiety disorders, Obsessive-compulsive disorder (OCD) and ADHD); Suicidal ideation (within the past 10 years) or lifetime occurrence of attempted suicide; Current depression - The Patient Health Questionnaire (PHQ-9) for Depression will be used to screen for current (within 2 weeks) depression. Potential subjects who score >9 (or who score >0 on item #9 ("Thoughts that you would be better off (...) . clonidine); Opiate medications for pain or sleep (non-opiate medication for pain or sleep will be allowed) Smokeless tobacco (chewing tobacco, snuff), cigars or pipes; Wellbutrin, bupropion, Zyban, Chantix, nicotine replacement therapy or any other smoking cessation aid. Alcohol abuse - The AUDIT (Alcohol Use Disorders Identification Test) questionnaire will be used to assess alcohol abuse. Potential participants will be asked the first two questions on the AUDIT questionnaire during the phone screen

2009 Clinical Trials

230. Tobacco Use in the Perinatal Period

. The assessment of tobacco addiction requires more than these two questions. Other indicators of addiction include: how difficult it has been to stop in the past, how much stop-smoking medication is required to control symptoms of withdrawal, and personal and family history of those conditions. Tobacco addiction is associated with depression, schizophrenia, panic disorder, attention deficit disorder, addiction to other drugs, alcohol dependence, family history of smoking, spousal abuse, poverty, culture (...) death syndrome, impaired development of the brain, attention deficit disorder, nicotine withdrawal at birth. ] 23 • “What are your concerns about the effects of smoking on your own health and on the baby’s?” 4.4 ASSIST Assist means: • Offering brief counseling, encouragement, support with planning, to boost the smoker’s self- efficacy/confidence that they can stop smoking • Helping the patient set a quit date and plan if she is ready to quit, and working with the smoker’s partner/support system when

2006 British Columbia Perinatal Health Program

231. Comorbidity of mental disorders and substance use

Comorbidity of mental disorders and substance use Comorbidity of mental disorders and substance use: A brief guide for the primary care clinician Comorbidity of mental disorders and substance use: A brief guide for the primary care clinician Monograph Series No. 71Comorbidity of mental disorders and substance use: A brief guide for the primary care clinician Drug and Alcohol Services South Australia 2008ISBN: 1-74186-772-X Online ISBN: 1-74186-773-8 Publications Number: P3 -4653 This work (...) is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be reproduced by any process without prior written permission from the Commonwealth. Requests and inquiries concerning reproduction and rights should be addressed to the Commonwealth Copyright Administration, Attorney-General’s Department, Robert Garran Offices, National Circuit, Barton ACT 2600 or posted at Comorbidity of mental disorders and substance use: A brief guide for the primary care

2008 Clinical Practice Guidelines Portal

232. Review of the evidence base for treatment of childhood psychopathology: externalizing disorders

of behaviour disorders included thioridazine, molindone and methylphenidate. Psychopharmacological treatment of attention-deficit hyperactivity disorder (ADHD) included desipramine, methylphenidate, pindolol, bupropion hydrochloride, amphetamine sulphate and adderall. Participants included in the review Studies that included children with a mean age of 6 to 12 years were eligible for inclusion. The majority of children in each study had to be aged 6 to 12 years. The included studies were of children (...) Subject indexing assigned by NLM MeSH Adolescent; Antisocial Personality Disorder /diagnosis /psychology /therapy; Attention Deficit Disorder with Hyperactivity /diagnosis /psychology /therapy; Attention Deficit and Disruptive Behavior Disorders /diagnosis /psychology /therapy; Child; Humans; Internal-External Control; Risk Factors; Substance-Related Disorders /prevention & Treatment Outcome; control AccessionNumber 12002006695 Date bibliographic record published 30/11/2004 Date abstract record

2002 DARE.

233. Pharmacological treatment of cocaine dependence: a systematic review

-morbidities, such as alcohol, marijuana, tobacco or heroin dependence, major depression, antisocial personality disorder, anxiety disorder, attention deficit disorder, dysthymia. Outcomes assessed in the review The following outcomes were reported to be of interest: retention in treatment, the number of people reporting adverse events, positive urine samples (for cocaine metabolites), craving, severity of dependence, amount of cocaine consumed and quality of life measures. How were decisions (...) of cocaine dependence were eligible for inclusion in the review. The drug treatments in the included trials were grouped into the following categories: antidepressants, carbamazepine, dopamine agonists, and miscellaneous. The antidepressants included desipramine, fluoxetine, ritanserin, gepirona, bupropion and imipramine. The dopamine agonists included amantadine and bromocriptine. The miscellaneous treatments included naltrexone, mazindol, lithium, disulfiram, phenytoin, nimodipine, lithium carbonate

2002 DARE.

234. Brain Changes in Children and Adolescents With Behavioral Problems

): National Institutes of Health Clinical Center (CC) ( National Institute of Mental Health (NIMH) ) Study Details Study Description Go to Brief Summary: Purpose: This study will examine brain activity in children age 10-18 with disruptive behavior problems, including conduct disorder (CD), oppositional defiant disorder (ODD), and attention deficit hyperactivity disorder (ADHD), compared with children without behavioral problems. Our goal is to examine differences in how emotions, social situations (...) : February 21, 2005 Last Update Posted: April 4, 2019 Last Verified: July 21, 2016 Keywords provided by National Institutes of Health Clinical Center (CC) ( National Institute of Mental Health (NIMH) ): Amygdala Orbital Frontal Cortex Serotonin Orbitofrontal Cortex Attention Deficit Hyperactivity Disorder ADHD Anti-Social Behavior Healthy Volunteer HV Additional relevant MeSH terms: Layout table for MeSH terms Disease Attention Deficit Disorder with Hyperactivity Hyperkinesis Mental Disorders Psychotic

2005 Clinical Trials

235. Effects of Adding Motivational Interviewing to Antidepressant Treatment for Hispanic Adults With Depression

Phase Depression Drug: Standard antidepressant therapy (SADT) Behavioral: Motivational antidepressant therapy (MADT) Not Applicable Detailed Description: Depression is a serious illness that affects a person's mood, thoughts, and physical well-being. There are multiple types of depressive disorders, with major depressive disorder being one of the most common. The following symptoms may be signs of major depression: persistent feelings of anxiety, guilt, or hopelessness; irregular sleep and appetite (...) as in the control arm. Drug: Standard antidepressant therapy (SADT) Treatment with medication will follow the Texas Medication Algorithm (TMA) for Depression. Antidepressant medications may include the following: citalopram (Celexa), escitalopram (Lexapro), paroxetine (Paxil CR), sertraline (Zoloft), venlafaxine XR (Effexor XR), bupropion SR (Wellbutrin SR), duloxetine (Cymbalta), nortriptyline (Pamelor), and mirtazapine (Remeron). Behavioral: Motivational antidepressant therapy (MADT) The same medication

2007 Clinical Trials

236. The Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) Genotype

as well as patients with schizophrenia. Atomoxetine is a drug that has been Food and Drug Administration (FDA) approved for Attention Deficit Disorder and allegedly increase the amount of the neurotransmitter dopamine in the frontal cortex of the brain. Condition or disease Intervention/treatment Phase Schizophrenia Memory Disorders Cognition Disorders Drug: Atomoxetine Procedure: Functional magnetic resonance imaging Procedure: Neuropsychological Testing Drug: Placebo Phase 2 Detailed Description (...) effect and a genotype effect on neuropsychological tasks that measure dorsolateral prefrontal cortex (DLPFC) executive function, mostly in individuals who share the val/val genotype with respect to the met/met genotype. Secondary Outcome Measures : Change in The Positive and Negative Syndrome Scale (PANSS) [ Time Frame: At 14th and 35th days ] The Positive and Negative Syndrome Scale (PANSS) is a 7-point rating scale with (1) indicating the absence of a symptom or behavior and (7) indicating the most

2007 Clinical Trials

237. Youth Smoking Cessation: Therapy +/- "The Patch"

a smoking-related disease (Fellows et al., 2002). Extant data suggest that three of every five adolescent smokers are nicotine-dependent, and that some subgroups of adolescents are at higher risk for dependence (e.g., daily or heavy smokers, incarcerated youth, youth in vocational schools, depressed youth, youth with Attention Deficit Hyperactivity Disorder (ADHD)). Adolescent tobacco smoking increases risk for a wide range of negative health consequences (Abrantes et al., 2005; Anda et al., 1990 (...) advances in smoking cessation will move towards a goal of personalized treatment. Such an individualized approach for adolescent smoking cessation will be informed by further investigation of the relationships between outcomes in this trial. To serve these goals, we propose the following program: Youths who smoke regularly will receive a 6 week intervention using "cognitive-behavioral motivational enhancement" (CBME) supplemented by nicotine replacement therapy (NRT), if youth and parents desire

2008 Clinical Trials

238. Study of Lunesta Versus Placebo for Sleep Problems Related to Smoking Cessation and Zyban

alcoholic beverage per day or greater than 7 alcoholic drinks per week. Meet DSM-IV criteria for a current diagnosis of major depressive disorder, panic disorder or post-traumatic stress disorder, or a current or past history bipolar disorder, schizophrenia, or anorexia or bulimia nervosa. Have a past history of major depression, with historical evidence of suicidal or homicidal behavior, or psychotic symptoms. Have the presence of suicidal or homicidal ideation, or significant impairment of social (...) Disorder Sleep Disorders, Intrinsic Dyssomnias Sleep Wake Disorders Nervous System Diseases Mental Disorders Substance-Related Disorders Chemically-Induced Disorders Bupropion Eszopiclone Antidepressive Agents, Second-Generation Antidepressive Agents Psychotropic Drugs Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Dopamine Agents Neurotransmitter Agents Physiological Effects of Drugs Cytochrome P-450 CYP2D6

2007 Clinical Trials

239. ICC-1132

replacement therapy for menopause, or the following medications for attention deficit hyperactivity disorder (pemoline [Cylert], methylphenidate HC1 [Ritalin, Ritalin-SR, Concerta], dextroamphetamine sulfate [Dexedrine, Adderall], bupropion HC1 [Wellbutrin, Wellbutrin-SR]) Receives allergy shots or uses allergy medications chronically Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the volunteer to understand and cooperate with the study (...) of neurological disease, as indicated by any of the following: History of seizures (other than febrile seizures as a child <5 years old) History of unconsciousness (other than a single brief "concussion") Recurrent severe headaches or a diagnosis of migraine headaches Focal neurological deficit on physical examination suggesting a pathologic process -Evidence of gastrointestinal disease, as indicated by any of the following: Recurrent diarrhea (>5 episodes during the past 6 months, each lasting at least 3

2008 Clinical Trials

240. Combined Pharmaco/Behavior Therapy in Adolescent Smokers

bupropion is also an antidepressant, this criteria is to minimize the confound of depressive disorder during the study. History of depressive disorders and current attention deficit hyperactivity disorder (ADHD) will not be an exclusion. We will use permuted block randomization procedure to balance the groups for ADHD. Pregnancy or lactation. The safety of bupropion in pregnancy and during lactation is not well studied. History of seizure disorder or predisposition to seizures (e.g., history (...) the hypotheses, 216 adolescent smokers will be recruited. Fifty-four adolescent smokers will be recruited in each of the four groups: bupropion SR only, bupropion SR + CM, CM + placebo, and placebo only. The cells will be balanced for gender and attention deficit hyperactivity disorder using permuted block randomization. A counseling intervention was added for all groups because it was reasoned that it would be unethical not to provide an active treatment to cigarette smoking adolescents. The counseling

2006 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>